Angelo Michele Carella. Show Affiliations »
Abstract
Entities: Chemical Disease Gene
Mesh： See more » Adenosine Triphosphate/metabolismAntineoplastic Agents/pharmacologyAntineoplastic Agents/therapeutic useAntineoplastic Combined Chemotherapy Protocols/therapeutic useBenzamidesBinding Sites/drug effectsCross-Over StudiesCytarabine/administration & dosageDisease-Free SurvivalDrug DesignDrug Resistance, NeoplasmDrugs, InvestigationalEuropeFusion Proteins, bcr-abl/antagonists & inhibitorsFusion Proteins, bcr-abl/geneticsFusion Proteins, bcr-abl/physiologyHematopoietic Stem Cell TransplantationHumansImatinib MesylateInterferon-alpha/administration & dosageLeukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapyLeukemia, Myelogenous, Chronic, BCR-ABL Positive/enzymologyLeukemia, Myelogenous, Chronic, BCR-ABL Positive/geneticsLeukemia, Myelogenous, Chronic, BCR-ABL Positive/surgeryMulticenter Studies as TopicNeoplasm Proteins/antagonists & inhibitorsNeoplasm Proteins/geneticsNeoplasm Proteins/physiologyPiperazines/administration & dosagePiperazines/pharmacologyPiperazines/therapeutic usePractice Guidelines as TopicProtein Kinase Inhibitors/pharmacologyProtein Kinase Inhibitors/therapeutic usePyrimidines/administration & dosagePyrimidines/pharmacologyPyrimidines/therapeutic useRandomized Controlled Trials as TopicTransplantation, HomologousTreatment Outcomesrc Homology Domains/drug effects
Substances： See more » Antineoplastic AgentsBenzamidesDrugs, InvestigationalInterferon-alphaNeoplasm ProteinsPiperazinesProtein Kinase InhibitorsPyrimidinesCytarabineImatinib MesylateAdenosine TriphosphateFusion Proteins, bcr-abl
Year: 2007 PMID： 17338645 DOI： 10.1586/14737140.7.3.249
Source DB: PubMed Journal: Expert Rev Anticancer Ther ISSN： 1473-7140 Impact factor: 4.512